Shuttle Pharmaceuticals Holdings, Inc.
Index- P/E- EPS (ttm)- Insider Own63.42% Shs Outstand13.28M Perf Week-
Market Cap483.51M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float4.86M Perf Month-
Income- PEG- EPS next Q- Inst Own- Short Float- Perf Quarter-
Sales- P/S- EPS this Y- Inst Trans- Short Ratio- Perf Half Y-
Book/sh-0.25 P/B- EPS next Y- ROA- Target Price- Perf Year-
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range11.77 - 126.26 Perf YTD-5.41%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-65.31% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low272.13% ATR48.27
Employees5 Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)- Volatility- -
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume1.56 Prev Close36.40
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume7.11M Price43.80
Recom- SMA2028.31% SMA5028.31% SMA20028.31% Volume1,719,144 Change20.33%
Sep-06-22 09:00AM  
Aug-31-22 01:20PM  
Aug-30-22 04:40PM  
Shuttle Pharmaceuticals Holdings, Inc., through its subsidiary, Shuttle Pharmaceuticals, Inc., focuses on the discovery, development, and commercialization of drugs for sensitizing cancers to radiation therapy. Its products in clinical stage include Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and soft tissue sarcomas; and Doranidazole, an injectable hypoxic cell radiation sensitizer for treatment of pancreatic, lung, and liver cancers. The company was founded in 2012 and is based in Rockville, Maryland.